Australia markets close in 38 minutes

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
64.89+0.23 (+0.36%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close64.66
Bid0.00 x 1000
Ask0.00 x 800
Day's range64.15 - 65.22
52-week range56.56 - 85.79
Avg. volume8,248,431
Market cap81.7B
Beta (5Y monthly)0.41
PE ratio (TTM)662.14
EPS (TTM)0.10
Earnings date28 Apr 2021 - 03 May 2021
Forward dividend & yield2.84 (4.39%)
Ex-dividend date12 Mar 2021
1y target est74.88
  • Editor's pick
    Yahoo Finance Video

    How COVID-19 transformed the biotech industry

    Moderna shares surge after U.S. regulators put a pause on the use of Johnson & Johnson's COVID-19 vaccine. Hartaj Singh, Oppenheimer Analyst joins Yahoo Finance Live to weigh in on the outlook for the biotech industry.

  • U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer
    Business Wire

    U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer

    Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Trodelvy® (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer (UC) who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor. The accelerated approval was based on data from the international Phase 2, single-arm TROPHY study. Of the 112 patients who were evaluable for efficacy, 27.7% of those treated with Trodelvy responded to treatment, with 5.4% experiencing a complete response and 22.3% experiencing a partial response. The median duration of response was 7.2 months (95% CI: 4.7-8.6). The Trodelvy U.S. Prescribing Information has a BOXED WARNING for severe or life-threatening neutropenia and severe diarrhea; see below for Important Safety Information.

  • Yahoo Finance Video

    Pfizer’s vaccine EUA expansion request is ‘extremely welcomed’: Doctor

    Dr. Shereef Elnahal, University Hospital CEO, Former NJDOH Commissioner, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on coronavirus vaccines.